Key result
Comprehensive review updates the epidemiology, pathophysiology, and clinical management of CTEPH.
Why the study?
Chronic thromboembolic disease and pulmonary hypertension are under-diagnosed complications of pulmonary embolism with challenging, aspecific presentations despite being potentially curable with recent therapies.
This review provides an update on the epidemiology, pathophysiology, and clinical management of chronic thromboembolic syndromes, emphasizing the need for clinical suspicion in patients with unexplained dyspnea or persistent symptoms after acute pulmonary embolism.
Supports CTEPH suspicion in unexplained post-PE dyspnea; extends prior reviews while leaving prospective validation open.
: Chronic thromboembolic disease (CTED), especially when associated with pulmonary hypertension (CTEPH), is a fearsome and under-diagnosed but potentially curable complication of pulmonary embolism, thanks to recent therapeutic options. Aspecific symptoms and signs make its diagnosis challenging, requiring clinicians to be ready to suspect its presence in patients with dyspnea of unknown origin or persistent symptoms after acute pulmonary embolism. The aim of this review is to provide an update to the general practitioner or the specialist physician on the state of the art regarding the epidemiology, pathophysiology and clinical management of chronic thromboembolic syndromes.
No takes yet. Share an insight, caveat, or question.
Albani et al. (2019) conducted a review in Chronic thromboembolic pulmonary hypertension (CTEPH). This comprehensive review provides an update on the epidemiology, pathophysiology, and clinical management of chronic thromboembolic pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: